Novartis will be the first to hit U.S. shores with a copy of a blockbuster biotech drug, winning FDA approval for its take on Amgen’s Neupogen and heralding a new era in biopharma.

…read more

Source: Novartis wins landmark approval for a biosimilar of Amgen’s Neupogen


0 No comments